BRPI0508365A - immunogenic compositions for chlamydia pneumoniae - Google Patents

immunogenic compositions for chlamydia pneumoniae

Info

Publication number
BRPI0508365A
BRPI0508365A BRPI0508365-6A BRPI0508365A BRPI0508365A BR PI0508365 A BRPI0508365 A BR PI0508365A BR PI0508365 A BRPI0508365 A BR PI0508365A BR PI0508365 A BRPI0508365 A BR PI0508365A
Authority
BR
Brazil
Prior art keywords
chlamydia pneumoniae
immunogenic compositions
self
polypeptide
individual
Prior art date
Application number
BRPI0508365-6A
Other languages
Portuguese (pt)
Inventor
Guido Grandi
Ratti Giulio
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of BRPI0508365A publication Critical patent/BRPI0508365A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçõES IMUNOGêNICAS PARA CHLAMYDIA PNEUMONIAE. A invenção se refere aos polipeptídeos para uso como um antígeno autotransportador. A invenção adicionalmente se refere aos métodos e usos de um polipeptídeo para uma função autotransportadora na preparação de um medicamento para a prevenção ou tratamento de uma infecção por Chlamydia pneumoniae ou para preparação de um ensaio para o diagnóstico de uma infecção por Chlamydia pneumoniae em um indivíduo. Um método também é provido para promoção de uma resposta imune em um indivíduo, por administração ao mesmo de um polipeptídeo para uso como um antígeno autotransportador.IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUMONIAE. The invention relates to polypeptides for use as a self-supporting antigen. The invention further relates to methods and uses of a polypeptide for a self-supporting function in the preparation of a medicament for the prevention or treatment of a Chlamydia pneumoniae infection or for the preparation of an assay for the diagnosis of a Chlamydia pneumoniae infection in an individual. . A method is also provided for promoting an immune response in an individual by administering to it a polypeptide for use as a self-supporting antigen.

BRPI0508365-6A 2004-03-02 2005-03-02 immunogenic compositions for chlamydia pneumoniae BRPI0508365A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54983204P 2004-03-02 2004-03-02
US64311005P 2005-01-12 2005-01-12
US64455205P 2005-01-19 2005-01-19
PCT/US2005/006588 WO2005084306A2 (en) 2004-03-02 2005-03-02 Immunogenic compositions for chlamydia pneunomiae

Publications (1)

Publication Number Publication Date
BRPI0508365A true BRPI0508365A (en) 2007-07-24

Family

ID=34923269

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508365-6A BRPI0508365A (en) 2004-03-02 2005-03-02 immunogenic compositions for chlamydia pneumoniae

Country Status (6)

Country Link
EP (1) EP1729800A4 (en)
JP (1) JP2007526318A (en)
BR (1) BRPI0508365A (en)
CA (1) CA2557353A1 (en)
RU (1) RU2006134631A (en)
WO (1) WO2005084306A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
HUE027400T2 (en) 2005-02-18 2016-10-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
CN102105786B (en) * 2008-07-25 2014-10-29 赛乐思迪斯有限公司 A diagnostic method
WO2010032138A2 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
ITMI20090946A1 (en) 2009-05-28 2010-11-29 Novartis Ag EXPRESSION OF RECOMBINANT PROTEINS
CN102740882A (en) 2009-08-27 2012-10-17 诺华有限公司 Adjuvant comprising aluminium, oligonucleotide and polycation
MX2012002723A (en) 2009-09-02 2012-04-11 Novartis Ag Immunogenic compositions including tlr activity modulators.
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
ES2630029T3 (en) 2010-12-14 2017-08-17 Glaxosmithkline Biologicals Sa Flow cytometry analysis of adsorbed materials in metal salts
RU2013144207A (en) 2011-03-02 2015-04-10 Новартис Аг COMBINED VACCINES WITH REDUCED DOSES OF ANTIGEN AND / OR ADJUVANT
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
LT2822947T (en) 2012-03-07 2016-10-10 Glaxosmithkline Biologicals Sa Arginine salts of a tlr7 agonist
JP6345603B2 (en) 2012-03-08 2018-06-20 ノバルティス アーゲー Adjuvanted formulation of booster vaccine
JP6990522B2 (en) * 2017-04-11 2022-02-03 シスメックス株式会社 A method for measuring the immune stimulus response of immune cells, a method for determining the ability of immunological synapses to form in immune cells, and a cell analyzer.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
EP1297005B1 (en) * 2000-07-03 2009-08-26 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia pneumoniae

Also Published As

Publication number Publication date
JP2007526318A (en) 2007-09-13
EP1729800A2 (en) 2006-12-13
WO2005084306A3 (en) 2006-05-26
CA2557353A1 (en) 2005-09-15
WO2005084306A2 (en) 2005-09-15
RU2006134631A (en) 2008-04-10
EP1729800A4 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
BRPI0508365A (en) immunogenic compositions for chlamydia pneumoniae
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
NL300897I2 (en) Neisseira meningitidis serogroup B recombinantly lipidated fHbp subfamily A05 protein
CL2007003635A1 (en) COMPOUNDS DERIVED FROM 6-AMINO-PURIN-8-ONA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCESS TO PREPARE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF ALLERGIC, VIRAL OR CANCER DISEASES.
BRPI0708519A8 (en) virosome-like vesicle, pharmaceutical composition, use of at least one virosome-like vesicle, method of treatment and / or prophylaxis of a hiv infection, and kit for inducing an immune response against a gp41 protein of a human immunodeficiency virus
DK2280721T3 (en) Indoleamin-2,3-dioxygenase-based immunotherapy
BRPI0409459A (en) New Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
BRPI0912411A8 (en) use of a human interleukin-2 mutein (hil-2 mutein) or a fragment thereof, pharmaceutical composition for the treatment and / or prophylaxis of an autoimmune disease, use of human interleukin-2 mutein (hil-2 mutein) 2) or a section thereof, for the formation of regulatory t cells (treg) in an organism, method for treatment and / or prophylaxis of an autoimmune disease in an organism, method for formation of regulatory t cells (treg) in an organism organism, method for formation of regulatory t cells (treg) in vitro.
BR112014004860A2 (en) influenza virus antibody compositions
BR112013005907A2 (en) parenteral pharmaceutical composition, methods for treating and preventing an HIV infection, and use of a pharmaceutical composition
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
UY29377A1 (en) NEW LIQUID FORMULATIONS OF ROTAVIRUS, ITS PREPARATION AND ITS USES.
CO6640289A2 (en) Compositions of anti-nerve growth factor antibodies (ngf)
AR035586A1 (en) COMPOSITION OF VACCINE, EQUIPMENT, METHODS TO INCREASE THE IMMUNE RESPONSE, USE OF A DERIVATIVE OF 1H-IMIDAZO (4,5-C) QUINOLIN-4-AMINA IN THE MANUFACTURE OF A MEDICINAL PRODUCT, AND COMBINATION OF COMPONENTS FOR SEPARATE, SEQUENTIAL ADMINISTRATION OR CONCOMITANT FOR USE IN DNA VACCINATION
CL2007001847A1 (en) INTRAMUSCULAR OR SUBCUTANEOUS PHARMACEUTICAL COMPOSITION INCLUDING TMC278 (RILPIVIRINE); PROCESS TO PREPARE THE COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF HIV INFECTION.
BRPI0415304A (en) methods of increasing an immune response to an antigen in a mammal, and reducing the severity of a cancer in a patient, combined preparation, pharmaceutical kit, and, uses an il-18 polypeptide or its bioactive fragment or variant, and an immunogenic composition
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
NO20045521L (en) Diarylurea derivatives useful for the treatment of protein kinase-dependent diseases
CO6400149A2 (en) MYTHATIN LINK PROTEINS
CL2008003537A1 (en) 2-aminopyrimidine derived compounds, h4 receptor antagonists; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of an allergic, immunological or inflammatory disease or pain.
BRPI0415315A (en) methods of increasing an immune response to an antigen in a mammal, and reducing the severity of a cancer in a patient, combined preparation, pharmaceutical kit, and, uses an il-18 polypeptide or its bioactive fragment or derivative, and an immunogenic composition
WO2007059931A8 (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
WO2008017826A3 (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
HN2005030779A (en) NONADEPSIPEPTIDES ACILATED II
ATE458496T1 (en) HIV VACCINES AND METHODS OF APPLICATION

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US)

Free format text: ALTERADO DE: CHIRON CORPORATION

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.